Graft versus host disease

article

Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases

16 December 2020 | By Hervé Affagard (MaaT Pharma)

The human gut contains the largest ecosystem of microbial species having complex host-microbiome interactive networks that contribute to our physiology and regulate our immune system. An imbalance in this host-microbiome interaction is associated with disease and the ability to restore or stabilise the network by introducing a rich and diverse…

article

Could newborn stem cells revolutionise cell therapies?

8 December 2020 | By Hannah Balfour (European Pharmaceutical Review)

In this article, Dr Jaime Shamonki, Generate Life Science’s CMO, discusses how newborn stem cells derived from umbilical cord tissue could make mesenchymal stem cells less expensive and variable to produce.

news

Experimental arthritis drug prevents stem cell transplant complication

27 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)

An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants...

news

FDA grants orphan drug status to Cellect’s ApoGraft

5 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

The FDA has granted orphan drug designation for ApoGraft for the prevention of acute and chronic graft versus host disease...